oxaliplatin, irinotecan, folinic acid, fluorouracil — Competitive Intelligence Brief

oxaliplatin, irinotecan, folinic acid, fluorouracil (oxaliplatin, irinotecan, folinic acid, fluorouracil) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Platinum-based chemotherapy. Area: Oncology.

phase 3 Platinum-based chemotherapy Thymidylate synthase, topoisomerase I Oncology Small molecule

Target snapshot

oxaliplatin, irinotecan, folinic acid, fluorouracil (oxaliplatin, irinotecan, folinic acid, fluorouracil) — GERCOR - Multidisciplinary Oncology Cooperative Group. Oxaliplatin, irinotecan, folinic acid, and fluorouracil work together to inhibit thymidylate synthase and DNA synthesis, leading to cell death in rapidly dividing cancer cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
oxaliplatin, irinotecan, folinic acid, fluorouracil TARGET	oxaliplatin, irinotecan, folinic acid, fluorouracil	GERCOR - Multidisciplinary Oncology Cooperative Group	phase 3	Platinum-based chemotherapy	Thymidylate synthase, topoisomerase I
Neoadjuvant chemotherapy Folfirinox, 4 cycles	Neoadjuvant chemotherapy Folfirinox, 4 cycles	University Hospital, Bordeaux	phase 3	Combination chemotherapy regimen	Multiple: thymidylate synthase, topoisomerase I, DNA (cross-linking)
Eloxatin	Oxaliplatin	Yakult Honsha	marketed	Platinum-based chemotherapy agent	DNA	2002-01-01
Carboplatin Injection	Carboplatin Injection	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	marketed	Platinum-based chemotherapy agent	DNA
Oxaliplatin;Capecitabine	Oxaliplatin;Capecitabine	Hebei Medical University	marketed	Platinum-based chemotherapy combination; antimetabolite	DNA (oxaliplatin); thymidylate synthase (capecitabine/5-FU)
Carboplatin or Cisplatin	Carboplatin or Cisplatin	Second Hospital of Shanxi Medical University	marketed	Platinum-based chemotherapy agent	DNA
carboplatin periocular injection	carboplatin periocular injection	Sun Yat-sen University	marketed	Platinum-based chemotherapy agent	DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Platinum-based chemotherapy class)

1. Jiangsu HengRui Medicine Co., Ltd. · 2 drugs in this class
2. GERCOR - Multidisciplinary Oncology Cooperative Group · 2 drugs in this class
3. Holy Name Medical Center, Inc. · 2 drugs in this class
4. Sun Yat-sen University · 2 drugs in this class
5. Hoffmann-La Roche · 2 drugs in this class
6. Centre Oscar Lambret · 1 drug in this class
7. Centre Leon Berard · 1 drug in this class
8. AstraZeneca · 1 drug in this class
9. Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · 1 drug in this class
10. CatalYm GmbH · 1 drug in this class